Ameet Hingwe, MD
Infectious Disease · Altamonte Springs, FLNPI 1073721486
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $635 of the $784 with a category attached, or 81.0%. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 24.9% of the total. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 31 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$195
- Insmed, Inc.$112
- Merck$83
- Shionogi Inc$82
- La Jolla Pharmaceutical Company$72
- Tetraphase Pharmaceuticals, Inc.$52
- plus $188 from 6 others
What the payments were for
- Food & beverage$63581%
- Education$14919%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $195 |
| Insmed, Inc. | 6 | $112 |
| Merck | 4 | $83 |
| Shionogi Inc | 4 | $82 |
| La Jolla Pharmaceutical Company | 3 | $72 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| AbbVie | 2 | $40 |
| Viiv Healthcare Company | 1 | $28 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$784 in reported general payments places this provider in the 50th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $105,478 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $62,088 |
| Daptomycin | 22 | $6,624 |
| Meropenem | 17 | $4,737 |
| CeftriaxoneCeftriaxone Sodium | 15 | $3,057 |
| Linezolid | 13 | $1,116 |
| Doxycycline Hyclate | 17 | $261 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $138 |
| Cephalexin | 15 | $136 |
| Cefdinir | 14 | $120 |
| Levofloxacin | 25 | $83 |
| Metronidazole | 13 | $75 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Altamonte Springs
- Juan DiazAltamonte Springs$980K
- Christopher CooperAltamonte Springs$278K
- Jason SniffenAltamonte Springs$174K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.